Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Verdant Robotics Delivers First Multi-Action Autonomous Farm Robot for Specialty Crops

Verdant Robotics

To meet farmers’ demands for more sustainable and profitable growing practices, Verdant Robotics announced the expansion of its robot-as-a-service (RaaS) model to ensure access for more specialty crop farmers today. Founded in late 2018 by a leading roboticist, a software engineer, and a California farmer, Verdant has raised $21.5 million to develop the industry’s first multi-action, autonomous farm-robot capable of millimeter-accurate spraying, laser weeding, and AI-based digital crop modeling. Together with farming partners, Verdant uses these tools to deliver better outcomes: larger produce, greater yields and significant savings. Verdant has already contracted to service approximately 40% of the U.S. carrot market exclusively for the next five years and is currently scaling to meet the needs of the U.S. multi-billion-dollar fruit and vegetable industry. “Farmers told us not to give them more data, but to figure out what to do with the mountains of data they already have, or better yet just go do it,” said Gabe Sibley, PhD., co-founder and CEO, who brings more than 20 years of experience in geo-spatial computation and AI. “They want a complete solution that takes action in real-time and keeps farmers in control – all while improving profitability and automating dangerous, back-breaking field work.” Sustainability, Profitability Driving Interest in Farm Robotics Investment into farm robotics as an enhancement to labor, profitability, and sustainability has been building for years. Agricultural robotic startups brought in $491 million in investment during the first half of 2021, a 40 percent increase over the same period in 2020, according to AgFunder, but to-date, actual on-farm robotics has mostly been on a trial basis. Following successful large-scale roll-out over the past 18 months, Verdant logged thousands of hours in 2021 and is already proven on multiple crops. “Today, Verdant machines are in the field all-day, every-day helping farmers achieve superhuman efficacy,” said Sibley. Combining multiple technologies, the company’s 6-row and 12-row commercial implements can treat up to 4.2 acres per hour, achieving a higher weed-removal rate per acre than other technology or human ability, and reducing chemical usage by up to 95 percent. Simultaneously, its autonomous software system collects data and uses machine learning capabilities to optimize yield and growing outcomes, ultimately unlocking new revenues to help farmers reach profitability and sustainability goals. “ Verdant Robotics ’ ability to digitize the farm enables precision technology at a level never before possible for specialty crops, removing the choice between environmental stewardship and profitability,” said Cannon Michae l, a sixth-generation California farmer and CEO of Bowles Farming Company. “With the unique combination of automation and insight, farmers can collectively manage precious resources – like water – while maintaining or improving yields.” RaaS Delivers AI, Robotics and Science to Farms of All Sizes, Faster Verdant’s computational robotic and autonomous software systems combine decades of advancements in scientific fields – including computer vision, artificial intelligence, robotics, GPS-denied navigation, chemistry, and soil and plant sciences – to achieve the next generation of crop production. “Verdant’s platform stands apart due to its integrated software and hardware that is applicable across a variety of high value crops,” said Steve Jurvetson, co-founder of Future Ventures and early investor into Verdant Robotics. “Drawing on expertise from Google X, NASA and several autonomous vehicle companies, the team has quickly delivered solid technology that ensures a growth path capable of addressing the global $8 trillion food and agriculture market and positions them well to meet the needs of farmers in adjacent markets and geographies.” “Together with their customers, Verdant is driving a shift in agriculture akin to the transformation we’ve seen in aerospace and automotive when computation is brought to bear,” Jurvetson added. Verdant leveraged investments from leading agriculture investors, including AgFunder, Autotech Ventures, Cavallo Ventures, DCVC Bio, and Future Ventures, among others. Building upon these investments, the company is expanding its platform with plans to commercialize a precision multi-action machine for orchards by 2023 – delivering another first for the specialty crop industry. Over the next several years, Verdant Robotics aims to deliver complete robotics solutions globally to help improve the quality, profitability and stewardship of important food crops and thereby feed growing populations more sustainably and nutritiously. About Verdant Robotics: Together with growers, we are building sustainable, high-fidelity farming: spatially, temporally, and physically working the farm at a precision, accuracy, frequency and scale never before possible. At Verdant we believe environmentally conscientious robotic farming is the future of agriculture. Our goal is to transform how food is grown while improving the lives of farmers, workers and rural communities. By digitizing the farm at sub-millimeter scale, indexing it, and taking actions that unlock new value, we are providing our customers with superhuman farming tools. To learn more, visit www.VerdantRobotics.com. Contact Details AgTech PR for Verdant Robotics Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.verdantrobotics.com

February 22, 2022 08:30 AM Central Standard Time

Image

Modivcare Launches Non-Emergency Medical Transportation Provider Academy to Champion Success and Engagement

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions focused on improving patient outcomes, today announced the launch of Modivcare Academy. The innovative program supports transportation providers who own, work for, or operate non-emergency medical transportation (NEMT) companies by providing education, networking opportunities, and training resources. “The introduction of Modivcare Academy is an extension of our purpose, to ensure greater access to care by serving the needs of our communities,” said Daniel Greenleaf, President and CEO of Modivcare. “Our unique program, offered to emerging NEMT companies that contract with us, supports the ongoing business success of transportation providers who are a driving force for positive change within their communities.” Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. “We are strongly committed to investing in the success of transportation providers because they serve a critical role in breaking down the barriers that stand in the way of access to care,” added Greenleaf. “Our transportation providers represent a broad and diverse pool of businesses, including disadvantaged, small, minority, and women-owned firms who are committed to providing safe and reliable transportation to the patients we jointly serve. We were overwhelmed by the positive response to our Chicago event and look forward to hosting future events in other communities in 2022.” “As transportation providers, we have faced many COVID-19 challenges, but we have stayed focused and have overcome these hurdles by concentrating on our patients,” said Brisa Berumen-Dixon, a transportation provider with Seabreeze NEMT, Rockford, Illinois. “The most rewarding part of what we do is improving the quality of life for individuals within our hometown communities, which is made possible through our relationship with Modivcare.” To further improve the driver experience and support their business success, Modivcare also launched a “Voice of the Customer” survey program to collect real-time feedback and a Transportation Advisory Council to support the needs of transportation providers. Modivcare’s non-emergency medical transportation services provide access to safe, reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its more than 6,500 transportation providers and provides more than 75 million trips annually to 30 million patients across the nation. Modivcare Academy empowers drivers with information and insights about the latest innovative technology, provides industry best-practices training, and offers resources to support running an NEMT business. The program was kicked-off in Chicago at the December 2021 inaugural Modivcare Academy event that featured subject matter experts offering insights about strategic growth, marketing and sales, customer engagement, operations, financial management, and technology adoption. # # # # About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and nutritional meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Kate Zerone Senior Manager, Communications kate.zerone@modivcare.com Kim Warth Amendola Communications kwarth@acmarketingpr.com

February 22, 2022 09:30 AM Eastern Standard Time

Image

Brush Up on Oral Health: Technology For Your Mouth Leading To Healthy, Confident Smiles

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/UIgoM06hR04 How do you get that ‘fresh from the dentist’ clean feeling on the 360+ days you’re not at the dentist? You turn to a revolutionary kit that integrates advanced technology to deliver brighter, whiter smiles and cleaner, healthier teeth. The result is that consumers look and feel their best and enjoy greater confidence as they go about their day. Built by dental professionals, izzoTM was developed by fourth-generation family-owned Premier Dental, a global developer and manufacturer of dental and medical products that has been in business for 100+ years, with a presence in 76 countries. Julie Charlestein, the President and CEO of Premier Dental, conducted a nationwide media tour to discuss the launch of izzo TM, an innovative new direct to consumer initiative designed to elevate at-home oral care. While brushing your teeth regularly is certainly important, izzo TM is the first and only 4-in-1 oral care system that goes significantly beyond just the typical toothbrush to give your teeth a whole new level of clean. izzo is technology for your mouth leading to healthy, confident smiles. izzo not only helps you brush effectively, it helps you polish to remove surface stains for a brighter, whiter smile; scale to remove plaque and debris between teeth; and sanitize your brush to ensure it’s germ-free for your next use. Best of all, it gives you that ‘fresh from the dentist’ clean feeling and a healthy confidence to look and feel your best. The revolutionary izzo system is currently available online for purchase at www.izzosmile.com for $129.95. For more information or to read first-hand product reviews, please visit www.izzosmile.com. About izzo TM izzo TM is the revolutionary 4-in-1 home oral care system that helps consumers look and feel their best through healthier, whiter smiles. izzo includes a toothbrush, polishing system (polisher & enamel polishing paste), scaler and sanitizer. Made in partnership with Premier ® Dental Products Company, a 4th generation, family-run business established in 1913, izzo reflects the knowledge of over 100 years in developing professional-grade oral care products. This differentiated product introduces innovative in-home dental care directly to consumers through an easy-to-use kit and a convenient Subscribe & Save program. For more information, please visit www.izzosmile.com. About Premier Dental ® Products Company Premier Dental ® is a global privately-held business dedicated to delivering inspired solutions for daily dentistry. Dental professionals have turned to Premier for over 100 years as a leader in bringing innovative products to market that improve their daily procedures, practices and patient outcomes. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 18, 2022 01:54 PM Eastern Standard Time

Video

Quotient Sciences Completes Integration Of Drug Substance Into Translational Pharmaceutics® Platform

Quotient Sciences

Quotient Sciences – a global drug development and manufacturing accelerator offering a suite of services to clients in the pharmaceutical and biotech industry – announces that it has integrated drug substance into its flagship Translational Pharmaceutics ® platform. The newly integrated service unites drug substance, drug product and clinical testing activities all within a unified organization and under a single project manager. The full integration of drug substance R&D and manufacturing follows a year after the company’s acquisition of its Alnwick, UK site and provides a more streamlined approach from candidate selection through to commercialization. Quotient Sciences Translational Pharmaceutics ® approach – combining manufacturing and clinical dosing at a single organization – enables innovators to adjust formulations and dosing in real time. “Our Translational Pharmaceutics ® platform is now in its 15 th year and has accelerated development timelines for more than 500 drug programs. We remain the only outsourcing partner able to offer innovators the ability to manufacture, release, and dose under one organization. This approach is proven to shave 12-months of timelines and, by adding drug substance synthesis, the timeline from candidate selection to clinic can be a further accelerated by 2-4 months,” commented Mark Egerton, CEO of Quotient Sciences. Translational Pharmaceutics ® was developed in consultation with the MHRA & FDA and employs a rapid “make-test” cycle, where drug products are manufactured, released, and dosed in a clinical study in days rather than months. This means biotechs and pharma companies can fast track molecules from First in Human (FIH) through Proof of Concept (POC). “By fully integrating drug substance with drug product and clinical testing activities, Quotient Sciences can closely align manufacturing and dosing workflows, greatly improving R&D efficiencies, and increasing the potential for clinical and commercial success,” stated Peter Scholes, CSO of Quotient Sciences. “In fact, an independent study by the Tufts Center of the Study of Drug Development (CSDD) showed Translational Pharmaceutics delivered $200milllion in drug development cost saving per approved drug.” “Our purpose has always been to bring new medicines to patients faster, and our new capabilities in drug substance continue to break down traditional industry silos. As we look to the future, Quotient will continue to bring on new services that further integrate drug development and streamline the outsourcing needs of our customers,” added Egerton. [1] https://www.quotientsciences.com/news/tufts-csdd-demonstrates-multi-million-dollar-benef/ About Quotient Sciences Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information visit quotientsciences.com. Contact Details De Facto Communications Abdul Khalifeh +44 20 3735 8165 a.khalifeh@defacto.co.uk Company Website https://www.quotientsciences.com/

February 17, 2022 09:12 AM Eastern Standard Time

Image

VinFuture foundation officially launches the call for 2022 VinFuture Prize nominations

Vingroup

HANOI, VIETNAM - Media OutReach - 17 February 2022 - The VinFuture Prize has officially opened the nomination portal for the second season from February 16th until May 17th, 2022. The 2022 season of VinFuture Prize is looking for scientific inventions and innovations that can help revive the world and build up sustainable development after the pandemic. The Laureates of the VinFuture Grand Prize 2021 Following the success of the inaugural VinFuture Prize with 4 honored breakthroughs in science and technology that can positively impact humanity on a global scale – The second season of the Prize has been launched and welcomed by the international community of science. The focus of the VinFuture Prize’s second season is to honor outstanding scientific innovations that can help reimagine post-pandemic life and stimulate sustainable development. This reflects VinFuture’s consistent vision and mission of “Science for humanity”. If health protection was the challenge of mankind in 2021, “Reshaping and Reviving” is the imperative that the world needs to cope with in 2022. Centering around the theme of “Reshaping and Reviving”, the second season of the VinFuture Prize hopes to motivate and inspire scientists around the world. Through the Prizes, VinFuture wishes to support people to overcome topical post-pandemic challenges and create positive changes for millions of human lives on earth this year. Commenting on the outstanding nominations of 2021 and looking forward to this year’s submissions, Prof. Sir Richard Henry Friend – Chair of the VinFuture Prize Council, said: “Last year’s prize awards celebrate very clearly how science and innovation can bring real global benefits for health. However, humankind faces big challenges in many other areas, including natural resource consumption, the move to zero carbon to avoid damaging climate change, and others. This year we want to reach as widely as we can, across disciplines and across continents, to broaden the scope and impact of the VinFuture Prizes in reviving the post-pandemic world.” To be eligible for participating in the VinFuture Prize 2022, the applications are required to meet the nomination criteria* and be nominated by reputable organizations/individuals in the field of science and technology around the world. Nominations will be evaluated in the pre-screening and selection stages by the Pre-screening Committee and the VinFuture Prize Council respectively. Members of the Prize Council and Pre-screening Committee are top global scientists, inventors and laureates of the Nobel Prize, Turing Award, Millenium Technology Prize, and other global awards. Sharing about the expectations for the call for nominations of the second VinFuture Prize season, Prof. Văn-Chí Đặng, Scientific Director of Ludwig Cancer Research Institute (USA) and a member of the VinFuture Prize Council, said: “Science and technology is the answer to the challenges and urgent global problems that people are facing. In order to have more inventions that help change people’s lives regardless of origin, skin color, or ethnicity, for this year’s Prize, we expect to receive more exceptional scientific solutions, in more diverse fields, across more geographical areas, and from scientists regardless of age, gender, or nationality,… with the potential for application on a larger scale." The inaugural VinFuture Prize received tremendous support from the global scientific and technological community, with 599 quality nominations from scientists, researchers, and innovators from six continents. The VinFuture Grand Prize, valued at US$ 3 million, was awarded to a group of three scientists: Dr. Katalin Karikó (USA), Prof. Drew Weissman (USA), and Prof. Pieter Cullis (Canada) for the development of mRNA technology, paving the way for the production of effective vaccines to help prevent COVID-19 outbreaks. The VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields was awarded to Prof. Omar Yaghi (USA) for his pioneering work on the discovery and development of metal-organic framework materials (MOFs). The VinFuture Special Prize for Female Innovators was awarded to Prof. Zhenan Bao (USA) for the scientific advancements from her pioneering work on developing skin-inspired organic electronics materials. The VinFuture Special Prize for Innovators from Developing countries was granted to two scientists from South Africa, Prof. Salim Abdool Karim and Prof. Quarraisha Abdool Karim, whose research helps prevent HIV transmission and lessen the burden of the AIDS epidemic. 2022 online nomination portal: https://online.vinfutureprize.org/nomination For more information about the Prize: Detailed instructions on the nomination process and the Nomination Form: https://online.vinfutureprize.org/nomination FAQs: https://vinfutureprize.org/faqs/ The first-year VinFuture Prize Laureates were announced at the Award Ceremony on January 20th, 2022. Information about the awarded innovations can be found here: https://vinfutureprize.org/laureates/ *The ten major nomination criteria of the VinFuture Prize are: There should be clear evidence, or potential, for an end-product or service based on the solution, which has an everyday practical application; Solutions should have already benefited millions of people in the past 10 years for the Grand Prize, or have the potential to benefit millions of people in the next 10 years for the Special Prizes; Solutions should be aligned with one or more of the United Nation’s SDGs; Solutions must be scientifically proven (i.e., there should be clear evidence of passing relevant scientific trials, and in the case of research, it must be empirically proven or widely reviewed); Open to researchers or inventors who were involved in developing the underlying solutions, and not entrepreneurs or corporates who helped in the commercialization/diffusion of the technology; End-products of the research should benefit people globally, including those from developing and less developed countries, as well as lower-income and disadvantaged communities; Open to individuals or teams of researchers/inventors; Preferences are considered for nominees in the active stages of their careers; A nominator can only nominate one nominee/one group of nominees for each of the four Prize categories. Research/Solution/Invention can be underpinned in any discipline of science, engineering, or technology, including potentially multi-disciplinary approaches. About VinFuture Foundation: The VinFuture Foundation, established on December 20th, 2020 on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation initiated by Mr. Phạm Nhật Vượng, the Chairman of Vingroup JSC, Vietnam’s leading private conglomerate, and his wife, Mrs. Phạm Thu Hương. The Foundation was established to honor and facilitate breakthrough scientific research and technological innovations that have already contributed or have the potential to contribute to the betterment of life for millions of human beings globally while creating a more sustainable world for future generations. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. Contact Details Vingroup Media Contact v.nammh@vingroup.net Company Website https://online.vinfutureprize.org/nomination/s/welcome

February 17, 2022 08:30 AM Eastern Standard Time

Image

G Medical Innovations Announces that More than 200,000 LiveNow At-Home COVID-19 PCR Tests are Now Available at 4,000+ Circle K Locations Nationally, with 300,000 More to Ship in the Coming Weeks

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced today that more than 200,000 of its LiveNow COVID-19 PCR collection kit tests are now available at more than 4,000 Circle K convenience stores nationally. Another 300,000 kits will ship to the retailer within the next few weeks. The kits are expected to generate approximately $12 million in revenue, based on the expected return of at least 100,000 kit samples to the company’s testing lab. Circle K is one of the largest independent convenience store operators in the United States. “As a result of our highly successful partnership with McDade Products for brand development and national retail distribution, millions more of the LiveNow PCR Collection Kits are in production. They will continue to ship to Circle K stores and will fulfill significant orders for kits from other national retailers to be announced soon”, said Dr. Yacov Geva, President and CEO of G Medical Innovations. In response to a national shortage of COVID-19 test options, Pittsburgh-based McDade Products, LLC and G Medical Tests and Services, a division of G Medical Innovations, partnered in January to make several million COVID-19 PCR collection kit tests available for retailers. G Medical Innovations is a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions. McDade Products is a division of McDade Group, a specialty sales, marketing, and distribution company serving the U.S. retail industry. The LiveNow diagnostic PCR (polymerase chain reaction) test detects the presence or absence of SARS-CoV2, the virus that causes COVID-19. The PCR test type, which requires approved lab certification, has been widely recognized as more accurate because it is more sensitive than antigen tests. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. About McDade Group Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device, a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Prolongation Syndrome Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses delivery of purchase orders, anticipated revenue, production of additional LiveNow PCR Collection Kits, that it will continue to ship to Circle K stores and will fulfill significant orders for kits from other national retailers to be announced soon. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

February 16, 2022 07:00 AM Eastern Standard Time

AmeriLife Now Offers SimpliNow℠ Legacy from AIG

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing annuity, life and health insurance solutions, today announced that its agencies and affiliates are now offering SimpliNow Legacy SM from AIG (issued by American General Life Insurance Company), a simplified issue whole life insurance product specifically designed for middle-market American seniors. SimpliNow Legacy was designed to help policyholders lessen the burden of final expenses--including unpaid debt, medical bills or other household costs--on their loved ones. The product offers a unique limited-pay feature and death benefit coverage ranging from $5,000-$35,000. SimpliNow Legacy was created with middle-market Americans (ages 50 to 80 with a household income of $75,000 or less) in mind, including seniors, to help provide this growing demographic an additional layer of financial protection. For agents, SimpliNow Legacy was built for speed. This product features an instant-decision underwriting process, no post-sale paperwork, and the ability to draft credit card payments in real-time to instantly issue policies. This process includes: Electronic applications that tell agents early-on the type of coverage their clients can receive Instant underwriting decisions 100% of the time and early in the application process, with no additional underwriting, ever Instant issue capabilities for IGO and current dated apps paid with credit cards SimpliNow Quoter allows agents to easily quote their clients’ premiums before or during the application process “In the U.S., the median cost of a funeral is around $9,000*, and many older Americans are doing what they can to avoid passing those expenses onto their loved ones,” said Pat Fleming, Executive Vice President of Product Innovation and Corporate Actuary for AmeriLife. “We’re proud to be one of AIG’s exclusive partners in offering a groundbreaking product that provides consumers with the confidence that their final expenses will be addressed. The speed of the process at the point-of-sale is something that will help our agents work quickly and efficiently to help their clients secure coverage that will aid in preserving their legacies.” For more information on SimpliNow Legacy, visit www.amerilife.com to get in touch with an AmeriLife agency or affiliate. ### About AmeriLife AmeriLife’s strength is its mission: to provide financial solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 agents and advisors, more than 40 marketing organizations, and 50 agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. *Source: National Funeral Directors Association. Policies issued by American General Life Insurance Company (AGL), Houston, TX. Policy Forms: ICC21-21445, 21445, 21445-5, 21445-10, 21445-35, 21445-42, ICC21-21447, 21447, 21447-5, 21447-10, 21447-35 and 21447-42. Rider Numbers: ICC21-21468, 21468, 21468-5, 21468-10, ICC21-21469, 21469, 21469-5, 21469-10, ICC21-21470, 21470, 21470-5, 21470-35 and 21470-42. Issuing company AGL is responsible for financial obligations of insurance products and is a member of American International Group, Inc. (AIG). Guarantees are backed by the claims-paying ability of the issuing insurance company. AGL does not solicit, issue, or deliver policies or contracts in the state of New York. Products may not be available in all states and product features may vary by state. Please refer to the policy. This is not a preneed insurance contract or agreement. Benefits are payable to the beneficiary or beneficiaries as directed by the owner of policy. Premiums paid may exceed amount of coverage. For an estimate of the year the premiums may exceed the amount of coverage, divide the face amount by the annual premium. SimpliNow Legacy offers a limited death benefit in the first two years of the policy. Should death occur in the first two years, a death benefit will be equal to 110% of the premiums paid. In the event of suicide, the death benefit is limited to a refund of premiums paid less any outstanding loan amount. THIS POLICY DOES NOT GUARANTEE THAT ITS PROCEEDS WILL BE SUFFICIENT TO PAY FOR ANY PARTICULAR SERVICES OR MERCHANDISE AT TIME OF NEED OR THAT SERVICES OR MERCHANDISE SHALL BE PROVIDED BY ANY PARTICULAR PROVIDER. American General Life Insurance Company 2929 Allen Parkway, Houston, TX 77019, United States © 2022 American General Life Insurance. All Rights Reserved. AGLC201559 Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Company Website https://amerilife.com/

February 15, 2022 10:00 AM Eastern Standard Time

CURE Token Launches CURE Chain Development by Securing Technical Advisor Jim Nasr

CURE Token, LLC

Jacob Beckley, visionary founder of CURE Token and THE BECKLEY FOUNDATION philanthropist, has set his sights on another new and exciting venture in his quest to upend traditional approaches to medical research and to enable universal access to medical care, especially for the underserved. As COVID hampered the The Beckley Foundation's fundraising events and efforts, Beckley needed innovative, alternative ways to fund its commitments to active medical research programs. CURE Token was launched to fill funding gap, and instead exploded in a short time to a $52M market cap, enabling the expansion of the Beckley foundation's mission to include supplementing the devastating patient and family costs associated with childhood cancer care. "Supporting childhood cancer research, patients and their families is a compassionate effort, and I'm pleased we are able to make even a small difference", says Beckley, "but it's the tip of an iceberg fraught with underlying problems in an industry disinterested in change". He goes on to describe two fundamental healthcare industry problems at opposite ends of the delivery system. "Researchers need to share data, every day, real-time, in an anonymous, secure system. COVID vaccines are an example of the speed and acuity that can be brought to bear through real-time collaboration. That same process needs to be replicated every day, in every way, on every research project. By the time professional papers are published and peer reviewed, it's already old news". At the other end of the spectrum Beckley talks about his primary goal: patient access. "All the medical research, innovation and development in the world is worthless if patients are unable to access it due to economics or geography. Healthcare access should not be limited to the wealthy, the insured, or the geographically well located. Healing is for everyone." CURE Chain, Beckley's visionary concept to address both of these goals is becoming a reality, and he's harnessing the horsepower to make it happen sooner rather than later. Jim Nasr, a well-respected tech innovator and CEO of Acoer, an award-winning tech firm specializing in user friendly blockchain development will join Beckley in structuring and launching CURE Chain. Nasr is well versed in the healthcare industry, from his role as chief software architect for the Centers for Disease Control (CDC) in the US, his collaboration with Mayo Clinic's development of their connected diagnostics platform, and positions on a variety of key healthcare technology committees and related boards. https://images.squarespace-cdn.com/content/v1/5af858de1aef1df75ada4dce/4a886ac6-bbde-4bf9-8a2e-d191eabccf97/cure-chain-leadership.png?format=1000w "CURE Chain provides a novel opportunity to address the issues that Jacob has identified. As example, through use of Non-Fungible Tokens (NFTs) on a public Distributed Ledger Technology (DLT) network, we intend to reference clinical research and patient data uniquely, securely and in a privacy preserving manner. This DLT “anchoring” will significantly increase confidence on the authenticity of the underlying data and accountable monitoring and usage it," says Nasr. “We firmly believe that properly conceived DLT and blockchain integration as an underlayer of computational trust can lead to decentralized healthcare delivery and the leveling of the playing field—reducing the gap between the developed and underdeveloped health systems, the insured and uninsured, and the wealthy and the poor." Full CURE Chain implementation will proceed after the conclusion of the already underway key design activities. These include: Technical architecture design—on schedule, with the technical team already hard at work, identification of research organizations for piloting clinical trial data exchange, and the development of patient user experience models. "Financial institutions tried to thwart cryptocurrency development and growth, but it happened anyway by mass demand. CURE Chain will change a healthcare industry that doesn't know it's broken and has no motivation to change, and it will do it by mass demand," Beckley explains. "Once it catches on and people, both researchers and patients, see the value change will be monumental". A pretty bold, futuristic statement, but it comes from someone whose title is "Senior Vice President of Innovation, Product and Technology" at one of the country's acclaimed digital innovation firms, Fusion92. Perhaps it's time to pay attention. Contact Details Eric Brown +44 7960 044904 eric@curetoken.net

February 15, 2022 10:00 AM Eastern Standard Time

Image

QX Global Group Acquires Management Consulting & Advisory Services Firm Chazey Partners

QX Global Group

Together QX Global Group and Chazey Partners will provide end-to-end Business Transformation, Digital Services & Intelligent Automation, and Business Process Outsourcing (BPO) for Fortune 1000 companies and public sector organizations, including higher education, across the globe. QX Global Group, a Top 100 Business Process Outsourcing company, announced the acquisition of an 80% stake in Austin, Texas-based Chazey Partners, a world-class management consulting and advisory firm specializing in business and digital transformation. The Chazey Partners team brings decades of experience in implementing and operating world-class business support and shared services organizations around the globe, with expertise in Robotic Process Automation (RPA) and Artificial Intelligence (AI). Together, QX and Chazey Partners will work to deliver innovative solutions that cover transformative consulting, digital services, and business process outsourcing, customized to meet each client’s specific needs. “At QX, we have always focused on enabling transformation of our client’s businesses using our unique 3P approach of people, process, and platform, and we are thrilled that the addition of Chazey will allow us to help organizations solve their most significant barrier to growth – digital adoption and business transformation at scale, said Frank Robinson, Group CEO of QX Global Group. “Adding Chazey furthers our vision to provide integrated, end-to-end solutions to help our customers take advantage of the latest operating models and emerging technologies. I am also delighted to officially welcome Phil Searle onto QX Global Group’s Board as Chief Transformation Officer.” Chazey brings to the QX Global Group management consulting and advisory services with a global reach. Founded in 2006, Chazey Partners has demonstrated consistent and significant growth, with global representation in the United States, Canada, Mexico, Brazil, Costa Rica, Colombia, Ireland, Turkey, and India. Chazey’s consultants provide advice, support, and implementation expertise, covering strategy setting, business case production, program management, process optimization, technology enablement, training, and change management. “ Since founding the company, we have significantly expanded and evolved Chazey’s solutions to help numerous businesses and public sector organizations achieve operational excellence by transforming their business operations,’’ said Phil Searle, CEO and Founder of Chazey Partners. ‘’With QX, we have found a shared passion for empowering our clients to achieve world-class performance. By joining forces with QX, we will augment our near-shoring and offshoring capabilities by opening new Centers of Excellence (COEs) in India and Latin America. This is an exciting new chapter for Chazey Partners, our employees, and our customers.” The partnership of both trusted brands comes at a time when enterprises across the globe are adjusting to the post-pandemic world. In this environment, Chazey Partners is at the forefront of offering needed transformation solutions, helping enterprises optimize business operations and adopt the latest technologies for sustained growth. The QX-Chazey partnership will enable all clients to achieve a faster return on investment and add more value to their customers and employees. Barbara Hodge, Global Digital Editor at the Shared Services & Outsourcing Network (SSON), said, “This marks an exciting and timely development in the shared services and outsourcing space. SSON has collaborated with Chazey Partners for many years, and I am pleased to see such a highly respected group in the field of business transformation push forwards in extending its services to provide enterprise customers with the more holistic solutions they need right now. Adding Chazey Partners’ transformation capabilities to QX Global Groups’ BPO services, drives an end-to-end solution that connects consulting, digital and business process outsourcing. This aligns perfectly with the move to integrated business services, digitalization – driven by intelligent automation – and data analytics, that we are seeing across the shared services landscape. It’s also consistent with service providers moving to a ‘one-stop-shop’ solution for business transformation and digital needs. I am delighted at this news and look forward to engaging with the new partnership.” For QX Global Group: Corbett Keeling, London, and J. Sloan & Co, Dallas, Texas, provided corporate finance and transaction advice for QX Global Group; BDO LLP provided Due Diligence support across all entity geographies; legal support was provided by Munsch Hardt Kopf & Harr, P.C. For Chazey Partners: Sett & Lucas acted as transaction advisor, and Jackson Walker LLP provided legal support. About QX Global Group QX Global Group is a leading provider of business process management services. With over 17 years of accounting and recruitment process outsourcing experience, we help our clients unlock business value by improving process efficiencies and automation in the accounting and recruitment functions to enable business transformation. We have offices in the UK, USA, Canada, Australia, and India. About Chazey Partners Chazey Partners is a practitioner-led, global management consulting and advisory services firm. We bring real-life, practical, hands-on experience, empowering clients to strive for world-class performance, through Business Transformation, Shared Services, and Intelligent Automation. We help businesses and public sector organizations achieve operational excellence in the provision of mission-critical business services, including Finance, Human Resources, IT, Procurement, Contact Centers, Marketing, and Facilities Management. For over sixteen years, Chazey Partners has helped clients implement successful service delivery solutions; in the US & Canada, Latin America, Europe, the Middle East, Africa, Oceania, and Asia. Contact Details QX Global Group Vishal Kurani +44 20 8146 0808 vishal.kurani@qxglobalgroup.com Chazey Partners Leigh Knowles +1 855-692-6229 LeighKnowles@chazeypartners.com Company Website https://qxglobalgroup.com/

February 14, 2022 09:55 AM Eastern Standard Time

1 ... 239 240 241 242 243 ... 310